$58.34−$1.22 (−2.05%) on the dayAs of the close; data may be delayed.
BMY price, last 12 months
$68.09$45.79$58.34
Daily closes over the last 260 trading sessions: +25.0%. Highest close $68.09 on , lowest $45.79 on . Market data may be delayed.
Key stats
Previous close
$59.56
Open
$59.19
Day range
$57.88 – $59.30
52-week range
$45.27 – $68.64
Volume
13.7M
Avg volume (20 days)
10.2M
Market cap
$129.7B
Performance
1W−7.3%
1M−6.6%
3M−12.6%
6M−1.1%
YTD+9.1%
1Y+28.5%
vs S&P 500, 1Y+23.2 pts
Technicals and fundamentals
About Bristol-Myers Squibb Co.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Chart BMY with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full BMY chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)3.1%average true range, % of price
52w low $45.2752w high $68.64
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)12.90.57x Manufacturing median (22.6)
P/E (forward)8.7
PEG16.33
Price / sales2.38
Price / book5.10
EV / EBITDA—
P/E since Jun 111.9 – 15.0
Company figures as of Nov 19, 2026.
Analysts
ConsensusBuy2.5 on 1 (strong buy) to 5 (strong sell)
Analysts24
Average target$65.25+10.9% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Feb 4, 2027 (in 76 days)A year after its Feb 5, 2026 results release; the last came Oct 29, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
Paid, last 12 months$2.52quarterly
Yield at today's price4.28%
Change vs the year before+1.6%
Payout ratio56%share of earnings paid out
Oct 2$0.63Jul 2$0.63Apr 2$0.63Jan 2$0.63Oct 3$0.62Jul 3$0.62
Seasonality
+1.3
J
+3.8
F
+2.6
M
-7.5
A
-3.8
M
-0.2
J
+2.9
J
+1.4
A
-1.6
S
+1.1
O
+0.8
N
+3.0
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+2
+13
−3
−0
−6
+1
+13
+2
−7
+0
+16%
2025
+4
+1
+2
−18
−4
−4
−6
+9
−4
+2
+7
+10
−5%
2024
−5
+4
+7
−19
−6
+1
+15
+5
+4
+8
+6
−4
+10%
2023
+1
−5
+1
−4
−3
−1
−3
−1
−6
−11
−4
+4
−29%
2022
+4
+6
+6
+3
+0
+2
−4
−9
+5
+9
+4
−10
+15%
2021
−1
−8
+16
+5%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
The company demonstrated strong execution with 12% growth portfolio revenue growth, eight blockbuster medicines exceeding $1 billion in sales, positive late-stage clinical trial results, raised full-year EPS guidance, and $2 billion in cost savings. While facing a $1.5-2 billion revenue headwind in 2027 from patent expirations, management's strategic initiatives and pipeline momentum suggest resilience and long-term value creation.
BMS is sponsoring a Phase 1/2 clinical collaboration trial with Erasca to evaluate ERAS-0015 combined with navlimetostat (PRMT5 inhibitor) in MTAP-deleted pancreatic cancer. This represents a strategic partnership but is early-stage and does not directly impact BMY's core business or financial outlook.
Collaborating with BioNTech on pumitamig bispecific antibody in seven pivotal cancer studies, representing a potential future revenue stream but with uncertain timeline.
Developing izalontamab brengitecan (received FDA Breakthrough Therapy Designation in August 2025) and other ADC candidates. Strong pipeline presence in NSCLC market.
BMS is expanding its oncology pipeline by sponsoring a clinical trial combining its investigational PRMT5 inhibitor navlimetostat with a complementary RAS-targeting agent, potentially addressing an unmet need in MTAP-deleted pancreatic cancer with strong scientific rationale for the combination.
Partnering with BioNTech on pumitamig (PD-L1×VEGF-A bispecific) with seven pivotal oncology trials underway. Collaboration indicates strategic focus on next-generation oncology formats, but limited specific financial impact disclosed in this article.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.